BCAX — Bicara Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023658 ·
Last close
$21.69
Market Cap
$1.43B
52W High
$24.25
52W Low
$17.63
ADV30
526,787
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -60,242,000 | -56,211,000 | 553,599,000 | 323,462,000 | 39,641,000 |
| Dec 2025 | 0 | — | -41,122,000 | -37,386,000 | 430,994,000 | 96,685,000 | 29,542,000 |
| Sep 2025 | 0 | — | -40,676,000 | -36,330,000 | 424,688,000 | 171,673,000 | 21,908,000 |
| Jun 2025 | 0 | — | -32,018,000 | -27,388,000 | 453,587,000 | 436,606,000 | 18,391,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-116,236,000
Investing CF
$-217,513,000
Financing CF
$195,146,000
CapEx
$-346,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-415,177,000
Inventory
—
Receivables
—
ST Investments
$216,291,000
EBIT TTM
$-174,058,000
Pretax Income TTM
$-157,118,000
Interest Exp TTM
—
Analysts
13
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -155,604,000 | -137,950,000 | 430,994,000 | 29,542,000 | — | -106,834,000 |
| Dec 2024 | 0 | -82,389,000 | -67,995,000 | 509,996,000 | 18,121,000 | — | -74,751,000 |
| Dec 2023 | 0 | -39,889,000 | -51,985,000 | 233,982,000 | 382,751,000 | — | -45,628,000 |
| Dec 2022 | 0 | -37,656,000 | -37,845,000 | 6,703,000 | 105,506,000 | — | -32,076,000 |
TTM Snapshot
Revenues TTM
$3,160,000
NetIncome TTM
$-40,326,000
OpCashFlow TTM
$0
Assets (Latest)
$509,996,000
Forward EPS
$-3.63
Max Pain — expiry 2026-06-18
max pain strike: $20.00 · spot: $21.56 · call oi: 676 · put oi: 1,114
Expected Move to 2026-06-18:
±$4.20
(19.48%) —
implied range
$17.36 –
$25.76
· ATM straddle on $22.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVBP | ArriVent BioPharma, Inc. | $1.42B | $30.54 | — |
| KALV | KalVista Pharmaceuticals, Inc. | $1.44B | $27.00 | — |
| ATAI | AtaiBeckley Inc. | $1.44B | $3.92 | — |
| ARDX | ARDELYX, INC. | $1.41B | $5.69 | — |
| HROW | HARROW, INC. | $1.40B | $37.64 | — |
News headlines (Yahoo Finance, 1h cache)
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
2026-06-13 05:21 · Yahoo
Bicara (BCAX) Q4 2025 Earnings Transcript
2026-06-01 16:13 · Yahoo
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
2026-05-22 15:09 · Yahoo
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
2026-05-21 21:00 · Yahoo
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback
2026-05-19 13:09 · Yahoo
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
2026-05-15 23:02 · Yahoo
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
2026-05-15 22:56 · Yahoo
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
2026-05-14 21:09 · Yahoo
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-05-13 12:30 · Yahoo
Bicara Therapeutics Inc (BCAX) Q1 2026 Earnings Call Highlights: Strategic Advances and ...
2026-05-12 07:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.